";s:4:"text";s:5285:" the elderly or patients with hepatic insufficiency) at 2.5 mg [see Use in Specific Population (8.5, 8.6)].
If severe hypotension should occur, supportive measures including the use of intravenous vasopressor drugs should be instituted immediately. Start patients at increased risk for hypoglycemia (e.g. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.The side effects most frequently reported with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia.
Available for Android and iOS devices. However, patients with pheochromocytoma, cerebral vascular or renal insufficiency, or a severe cardiac reserve deficiency such as mitral insufficiency appear to be particularly prone to hypotensive reactions with phenothiazine compounds, and should therefore be observed closely when the drug is administered. Early detection of tardive dyskinesia is important. Furthermore, if any soreness of the mouth, gums, or throat, or any symptoms of upper respiratory infection occur and confirmatory leukocyte count indicates cellular depression, therapy should be discontinued and other appropriate measures instituted immediately.Liver damage as manifested by cholestatic jaundice may be encountered, particularly during the first months of therapy; treatment should be discontinued if this occurs. It is a highly potent behavior modifier with a markedly extended duration of effect. The esterification of fluphenazine markedly prolongs the drug’s duration of effect without unduly attenuating its beneficial action.Fluphenazine decanoate has activity at all levels of the central nervous system as well as on multiple organ systems. To increase the likelihood of detecting the syndrome at the earliest possible time, the dosage of neuroleptic drug should be reduced periodically (if clinically possible) and the patient observed for signs of the disorder. The maximum recommended dose is 20 mg once daily. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent Given the likelihood that a substantial portion of patients exposed chronically to neuroleptics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The patient should be carefully monitored, since recurrences of NMS have been reported.The use of this drug may impair the mental and physical abilities required for driving a car or operating heavy machinery.Physicians should be alert to the possibility that severe adverse reactions may occur which require immediate medical attention.Potentiation of the effects of alcohol may occur with the use of this drug.Since there is no adequate experience in children who have received this drug, safety and efficacy in children have not been established.Fluphenazine Decanoate Injectionmay cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries.
By deep intramuscular injection. The mechanism whereby its therapeutic action is exerted is unknown.Fluphenazine differs from other phenothiazine derivatives in several respects: it is more potent on a milligram basis, it has less potentiating effect on central nervous system depressants and anesthetics than do some of the phenothiazines and appears to be less sedating, and it is less likely than some of the older phenothiazines to produce hypotension (nevertheless, appropriate cautions should be observed – see sections on Fluphenazine Decanoate Injection is a long-acting parenteral antipsychotic drug intended for use in themanagement of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronicschizophrenics).Fluphenazine Decanoate Injection has not been shown effective in the management of behavioralcomplications in patients with mental retardation.Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage.Phenothiazine compounds should not be used in patients receiving large doses of hypnotics.Fluphenazine Decanoate Injection is contraindicated in comatose or severely depressed states.The presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate.Fluphenazine Decanoate Injection is not intended for use in children under 12 years of age.Fluphenazine Decanoate Injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.Elderly patients with dementia- related psychosis treated with antipsychotic drugs are at an increased risk of death. Test dose 12.5 mg, dose to be administered into the gluteal muscle, then 12.5–100 mg after 4–7 days, then 12.5–100 mg every 14–35 days, adjusted according to response.